<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48732">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471807</url>
  </required_header>
  <id_info>
    <org_study_id>2014-04</org_study_id>
    <nct_id>NCT02471807</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study of the Edwards FORMA Tricuspid Transcatheter Repair System</brief_title>
  <official_title>Early Feasibility Study of the Edwards FORMA Tricuspid Transcatheter Repair System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multi-center, prospective, early feasibility study to measure individual
      patient clinical outcomes and effectiveness, evaluate the safety and function, provide
      guidance for future clinical study designs and development efforts of the Edwards FORMA
      Tricuspid Transcatheter Repair System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The early feasibility study of the Edwards FORMA Tricuspid Transcatheter Repair System is a
      multi-center, prospective, early feasibility study to measure individual patient clinical
      outcomes and effectiveness, evaluate the safety and function, provide guidance for future
      clinical study designs and development efforts of the Edwards FORMA Tricuspid Transcatheter
      Repair System.

      Data collected in this clinical study will include safety and function of the
      investigational system as well as up to 3 year clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>30 days</time_frame>
    <description>Device success and freedom from device or procedure related SAE's at 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization rates for the underlying condition (Heart Failure)</measure>
    <time_frame>6-months, 1-Year</time_frame>
    <description>Re-hospitalization rates for the underlying condition (Heart Failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention rates for the underlying condition (Tricuspid Regurgitation)</measure>
    <time_frame>6-months, 1-Year</time_frame>
    <description>Re-intervention rates for the underlying condition (Tricuspid Regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA Class from baseline</measure>
    <time_frame>6-months, 1-Year</time_frame>
    <description>Change in NYHA Class from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test distance (meters) from baseline</measure>
    <time_frame>6-months, 1-Year</time_frame>
    <description>Change in 6 minute walk test distance (meters) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as assessed by the SF-12 and KCCQ questionnaires from baseline</measure>
    <time_frame>6-months, 1-Year</time_frame>
    <description>Change in Quality of Life as assessed by the SF-12 and KCCQ questionnaires from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tricuspid Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Edwards FORMA Tricuspid Transcatheter Repair System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edwards FORMA Tricuspid Transcatheter Repair System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards FORMA Tricuspid Transcatheter Repair System</intervention_name>
    <arm_group_label>Edwards FORMA Tricuspid Transcatheter Repair System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinically significant, symptomatic (NYHA Functional Class II or greater) functional
             or secondary, tricuspid regurgitation (per applicable guidelines) requiring tricuspid
             valve repair or replacement as assessed by the Heart Team

          2. NYHA Functional Class II or greater or signs of persistent right heart failure
             despite optimal medical therapy

          3. Determined by the 'HEART Team' (a minimum of one Cardiologist, and one Cardiac
             Surgeon) to be at high surgical risk for tricuspid valve repair or replacement and
             the benefit-risk analysis supports utilization of the investigational device

        Exclusion Criteria:See Protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Esther Gerteis</last_name>
    <phone>+41 79 601 53 18</phone>
    <email>Esther_Gerteis@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bertha Torres</last_name>
    <phone>949 250-2321</phone>
    <email>bertha_torres@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Makkar, MD</last_name>
      <phone>310-423-3977</phone>
      <email>Raj.Makkar@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Mitch Gheorghiu</last_name>
      <phone>310-423-6152</phone>
      <email>Mitch.Gheorghiu@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rajendra Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Wheeler</last_name>
      <phone>404-712-0131</phone>
      <email>lmwheeler@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Warren</last_name>
      <phone>404-912-9554</phone>
      <email>lisa.warren@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vasilis Babaliaros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desirae Howe-Clayton, RN</last_name>
      <phone>507-538-3529</phone>
      <email>howe.desirae@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mackram Eleid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ciprich, RN</last_name>
      <phone>973-971-7541</phone>
      <email>Christine.Ciprich@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>John M Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Dalton</last_name>
      <phone>212-342-1820</phone>
      <email>keb2114@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alex Kantor</last_name>
      <phone>212-305-4786</phone>
      <email>ak3697@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susheel K Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>June 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
